Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
October 20 2008 - 8:30AM
PR Newswire (US)
EXTON, Pa., Oct. 20 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc.
(AMEX:ILE) announced today that the Company will host an investor
conference call and webcast on Wednesday, October 22 at 4:30 PM
Eastern Time to present an analysis of the data from the Isolagen
Therapy(TM) Phase III pivotal studies (IT-R-005 and IT-R-006) for
the treatment of nasolabial folds, or wrinkles. On August 5, 2008,
Isolagen reported positive top-line efficacy and safety results
from these two studies, which met all primary endpoints and were
highly statistically significant. The call participants will
include Declan Daly, Isolagen's CEO, Dr. Stacy Smith, the Principal
Investigator in the Phase III wrinkle studies and Co-Principal
Investigator in the Phase II/III acne study, and Dr. Jeanne Novak,
Clinical and Regulatory advisor to Isolagen. A live webcast of the
presentation will be accessible on http://www.isolagen.com/. To
participate in the audio portion of the call, dial 1-800-299-0433
and enter passcode 78803320. An archived replay of the conference
call and webcast will be available for 90 days on
http://www.isolagen.com/ or by dialing 1-888-286-8010 and entering
passcode 63040312. About Isolagen, Inc. Isolagen(TM), Inc.
(AMEX:ILE) is an aesthetic and therapeutic company committed to
developing and commercializing scientific advances and innovative
technologies. The company's technology platform includes the
Isolagen Process(TM), a cell processing system for skin and tissue
rejuvenation which is currently in clinical development for a broad
range of aesthetic and therapeutic applications including wrinkles,
acne scars, burns and periodontal disease. Isolagen also
commercializes a scientifically-advanced line of skincare systems
through its majority-owned subsidiary, Agera(R) Laboratories, Inc.
For additional information, please visit http://www.isolagen.com/.
Isolagen Forward Looking Statements All statements in this news
release that are not based on historical fact are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 and the provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. While management has
based any forward-looking statements contained herein on its
current expectations, the information on which such expectations
were based may change. These forward-looking statements rely on a
number of assumptions concerning future events and are subject to a
number of risks, uncertainties, and other factors, many of which
are outside of our control, that could cause actual results to
materially differ from such statements. Such risks, uncertainties,
and other factors include, but are not necessarily limited to,
those set forth under Item 1A "Risk Factors" in the Company's
Annual Report on Form 10-K for the year ended December 31, 2007, as
updated in Item 1A. "Risk Factors" in the Company's Quarterly
Reports on Form 10-Q. We operate in a highly competitive and
rapidly changing environment, thus new or unforeseen risks may
arise. Accordingly, investors should not place any reliance on
forward-looking statements as a prediction of actual results. We
disclaim any intention to, and undertake no obligation to, update
or revise any forward-looking statements. Readers are also urged to
carefully review and consider the other various disclosures in the
Company's Annual Report on Form 10-K for the year ended December
31, 2007, as well as other public filings with the SEC since such
date. DATASOURCE: Isolagen, Inc. CONTACT: Mike Beyer of Sam Brown
Inc. for Isolagen, Inc., +1-773-463-4211, Web site:
http://www.isolagen.com/
Copyright
Isolagen (AMEX:ILE)
Historical Stock Chart
From May 2024 to Jun 2024
Isolagen (AMEX:ILE)
Historical Stock Chart
From Jun 2023 to Jun 2024